Experimentally, navitoclax kills cells in a very BAX/BAK-dependent fashion and leads to regression of lymphoid tumors in xenograft types. Skip to primary articles Thank you for checking out nature.com. That you are employing a browser Model with constrained support for CSS. To obtain the best practical experience, we endorse you https://albertol015kkd9.ttblogs.com/profile